New hope for Hard-to-Treat blood cancers? early trial of MS-553 begins
NCT ID NCT06979076
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental drug called MS-553 in 12 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to treatment. The main goal is to check the drug's safety and find the right dose. MS-553 works by blocking a protein (PKC-β) that may help cancer cells grow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MS-553 (a PKC-β inhibitor)
- What this could lead to
- If successful, this could point toward a new treatment option for people with CLL or SLL that has stopped responding to other therapies.
- What could go wrong
- This is a very early, small trial (12 people) focused on safety, not effectiveness. The drug may not work or could have side effects. It is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL (CHRONIC LYMPHOCYTIC LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could bone marrow from deceased donors cure blood cancers?
- New combo aims to shorten CLL treatment
- New CLL combo aims for Long-Term remission without lifelong pills
- New hope for older leukemia patients: targeted pill shows promise
- 4-Week vegan diet tested as CLL therapy
- Could dead donors provide Life-Saving bone marrow?